News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Pieris Presents Data and Reveals Targets for Anticalin® Bispecific PRS-190 at European Antibody Congress


11/29/2012 9:46:50 AM

FREISING, Germany--(BUSINESS WIRE)--In a presentation yesterday at the 8th Annual European Antibody Congress in Geneva, Switzerland, Pieris AG presented for the first time data for its PRS-190 bispecific Anticalin program targeting the Th17 pathway. The data revealed the generation of a highly specific and potent bispecific antagonist targeting IL-17 and IL-23, two key members of the Th17 family of cytokines, involved in autoimmunity and hyperinflammation. The single-gene multispecific drug candidate, whose individual building blocks could surpass existing available therapies against their respective target, creates several benefits ranging from efficacy, convenience, accelerated development timelines, ease of manufacturing and cost.

Read at BioSpace.com


comments powered by Disqus
Pieris
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES